Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases
J Dtsch Dermatol Ges. 2007 Oct;5(10):881-7.
doi: 10.1111/j.1610-0387.2007.06342.x.
[Article in
English,
German]
Authors
Detlef Zillikens
1
, Kurt Derfler, Rüdiger Eming, Gerhard Fierlbeck, Matthias Goebeler, Michael Hertl, Silke C Hofmann, Franz Karlhofer, Ocko Kautz, Martin Nitschke, Andreas Opitz, Sven Quist, Christian Rose, Stefan Schanz, Enno Schmidt, Iakov Shimanovich, Michael Michael, Fabian Ziller
Affiliation
- 1 Department of Dermatology, University of Lübeck, Germany. detlef.zillikens@uk-sh.de
Abstract
Despite the use of high-dose systemic corticosteroids in combination with other immunosuppressants, in some patients with autoimmune bullous diseases only insufficient improvement is achieved. In these cases and in acute severe disease, adjuvant immunoapheresis has been increasingly used. A consensus meeting was held in mid-2005 in Hamburg, aiming at developing guidelines for the use of immunoapheresis in the treatment of autoimmune bullous diseases. This paper summarizes the experts' recommendations.
Publication types
-
Consensus Development Conference
MeSH terms
-
Autoimmune Diseases
-
Dermatology / standards
-
Germany
-
Humans
-
Immunoglobulins / therapeutic use*
-
Plasmapheresis / methods*
-
Practice Guidelines as Topic*
-
Practice Patterns, Physicians' / standards*
-
Skin Diseases, Vesiculobullous